DRUG | Bright Minds Biosciences Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	36.81 - 39.10
52 Week Range	0.9300 - 79.02
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	51,445
Average Volume	3,062,801
Shares Outstanding	6,948,490
Market Cap	268,559,139
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-03-22

Valuation
Profitability
Growth
Health
P/E Ratio	-63.36
Forward P/E Ratio	N/A
EPS	-0.61
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	0
Country	Canada
Website	DRUG

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

DRUG's peers: REVB, ZURA, PHIO, ZVSA, RNAZ, PYXS, EFTR, CYTO, ELEV, APGN, IMMX, VIRI, NAVB, ADTX, NRBO, DRMA, UNCY, INM, TNXP, XBIO

*Chart delayed

Analyzing fundamentals for DRUG we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see DRUG Fundamentals page.

Watching at DRUG technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on DRUG Technicals page.